Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.chom.2021.04.015 http://scihub22266oqcxt.onion/10.1016/j.chom.2021.04.015 33984285!8090990!33984285     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Host+Microbe 2021 ; 29 (6): 917-929.e4 Nephropedia Template TP {{tp|p=33984285|t=2021. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans |pdf=|usr=}}{{33984285}} gab.com Text Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans JO: Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33984285 #FOAvip Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4% of individuals, with 82% and 79% exhibiting serum and IgG neutralization, respectively. Approximately 3% of individuals demonstrated exceptional SARS-CoV-2 neutralization, with these "elite neutralizers" also possessing SARS-CoV-1 cross-neutralizing IgG. Multivariate statistical modeling revealed age, symptomatic infection, disease severity, and gender as key factors predicting SARS-CoV-2-neutralizing activity. A loss of reactivity to the virus spike protein was observed in 13% of individuals 10 months after infection. Neutralizing activity had half-lives of 14.7 weeks in serum versus 31.4 weeks in purified IgG, indicating a rather long-term IgG antibody response. Our results demonstrate a broad spectrum in the initial SARS-CoV-2-neutralizing antibody response, with sustained antibodies in most individuals for 10 months after mild COVID-19. Twit Text FOAVip Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans ????Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33984285 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33984285 #FOAvip English Wikipedia <ref>{{Cite pmid|33984285}}</ref> Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans #MMPMID33984285 Vanshylla K; Di Cristanziano V; Kleipass F; Dewald F; Schommers P; Gieselmann L; Gruell H; Schlotz M; Ercanoglu MS; Stumpf R; Mayer P; Zehner M; Heger E; Johannis W; Horn C; Suarez I; Jung N; Salomon S; Eberhardt KA; Gathof B; Fatkenheuer G; Pfeifer N; Eggeling R; Augustin M; Lehmann C; Klein F Cell Host Microbe 2021[Jun]; 29 (6): 917-929.e4 PMID33984285show ga Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4% of individuals, with 82% and 79% exhibiting serum and IgG neutralization, respectively. Approximately 3% of individuals demonstrated exceptional SARS-CoV-2 neutralization, with these "elite neutralizers" also possessing SARS-CoV-1 cross-neutralizing IgG. Multivariate statistical modeling revealed age, symptomatic infection, disease severity, and gender as key factors predicting SARS-CoV-2-neutralizing activity. A loss of reactivity to the virus spike protein was observed in 13% of individuals 10 months after infection. Neutralizing activity had half-lives of 14.7 weeks in serum versus 31.4 weeks in purified IgG, indicating a rather long-term IgG antibody response. Our results demonstrate a broad spectrum in the initial SARS-CoV-2-neutralizing antibody response, with sustained antibodies in most individuals for 10 months after mild COVID-19. |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Antibodies, Neutralizing/*immunology[MESH] |Antibodies, Viral/*immunology[MESH] |COVID-19/*immunology[MESH] |Cohort Studies[MESH] |Female[MESH] |Humans[MESH] |Immunoglobulin G/immunology[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2[MESH] |Time Factors[MESH]Kinetics and correlates of the neutralizing antibody response to SARS-(epmc).pdf DeepDyve Pubget Overpricing